Small Molecule Inhibitors of Ab-Aggregation and Neurotoxicity

作者:Cheryl A. Hawkes;Vivian Ng;JoAnne McLaurin 刊名: 上传者:周云光

【摘要】Alzheimer disease (AD) is characterized pathologically by extracellular amyloid deposits composed of Ab peptide, neurofibrillary tangles (NFTs) made up of hyperphosphorylated tau, and a deficit of cholinergic neurons in the basal forebrain. Presently, only symptomatic therapies are available for the treatment of AD and these therapies have a limited time frame of utility. Amyloid disorders represent the effects of chronic Ab production and are not a secondary pathological effect caused by a distant trigger; therefore targeting Ab is a viable pursuit. In this review, we will discuss the various small molecule antiaggregation inhibitors that have been reported in the literature, with emphasis on compounds that are presently being investigated in clinical trials. Drug Dev Res 70 : 111–124, 2009. r 2009 Wiley-Liss, Inc.

参考文献

引证文献

问答

我要提问